NCT03625323View on ClinicalTrials.gov

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

PHASE2CompletedINTERVENTIONAL
Enrollment

187

Participants

Timeline

Start Date

February 18, 2019

Primary Completion Date

June 2, 2022

Study Completion Date

November 25, 2024

Conditions
NSCLCHNSCC
Interventions
DRUG

eftilagimod alpha

APC activator, MHC II agonist, LAG-3 fusion protein

DRUG

pembrolizumab (KEYTRUDA®)

anti-PD-1 antibody

Trial Locations (1)

77030

Oncology Consultants, Houston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Immutep S.A.S.

INDUSTRY

NCT03625323 - Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC | Biotech Hunter | Biotech Hunter